FINWIRES · TerminalLIVE
FINWIRES

Hershey's First-Quarter Results Likely to be Strong Amid 'Solid' Consumption Trends, RBC Says

作者

-- Hershey (HSY) is expected to post strong first-quarter results amid "solid" consumption trends, while the chocolate maker will likely affirm its 2026 outlook, RBC Capital Markets said Tuesday.

Scanner data indicate "solid" consumption at the total company level in the quarter, driven by strong gains in confection and salty snacks, the brokerage said in a note to clients. Hershey is scheduled to report first-quarter results Thursday.

"With an earlier Easter, confection data for the final week of March is up strong (over high-teen percentage)," Nik Modi, RBC's co-head of global consumer and retail research, said. "This level of growth would suggest that (Hershey) will be able to clear topline growth expectations."

RBC expects first-quarter earnings of $2.08 a share on revenue of $3.03 billion. Wall Street is looking for $2.05 and $3.03 billion, respectively, according to the note. Although the three-month period was guided to be "the strongest quarter on the topline," margins are expected to be pressured by high cost of inventory, Modi said.

The brokerage expects Hershey to reaffirm its full-year outlook given that the company is just one quarter through its fiscal year and maintained the outlook just recently. "That said, we see a more neutral risk to reward given the high bar that (Hershey) set for itself this year," Modi wrote.

Late last month, company said it continued to expect full-year adjusted EPS to grow 30% to 35% and net sales to rise 4% to 5%.

The management's tone was positive at its investor day, with its long-term outlook suggesting the company has EPS visibility through 2027, RBC said. "With that said, the proof is now in the pudding on whether (Hershey's) strategy can revert ongoing volume declines and market share losses."

The brokerage has a sector perform rating on Hershey's stock with a $212 price target.

Price: $187.29, Change: $+0.80, Percent Change: +0.43%

相关文章

Asia

Rua Bioscience指出,在监管审查期间,澳大利亚医用大麻处方量出现“显著萎缩”。

Rua Bioscience(NZE:RUA)周三向新西兰证券交易所提交的文件显示,由于澳大利亚药品管理局(TGA)正在对未经批准的产品进行安全性审查,澳大利亚医用大麻处方量出现“显著萎缩”。 然而,Rua补充道,尽管近期国际形势发展以及全球经济放缓的讨论,医用大麻在国际市场,尤其是在欧洲,正展现出“强劲的成熟和增长迹象”。 根据文件显示,该公司近期在加拿大(仅次于美国的世界第二大大麻市场)成立了RUA Genetics公司,进一步拓展了其在德国、澳大利亚、新西兰、捷克和英国的业务。 在澳大利亚,该公司预计监管审查完成后市场将出现重置,并正努力将其产品引入新的连锁诊所。 此外,Rua计划在未来几个月内将多款产品引入新西兰市场,并正在筹备计划于5月在捷克推出的产品。此外,该公司正寻求在英国扩张,计划通过新的渠道和连锁诊所整合其基因技术。 在德国,该公司认为,由于此前审查期间分销商减少了库存并缩减了进口规模,因此不太可能出现重大的监管变化,市场对稳定可靠的供应商需求强劲。Rua表示,德国市场依然竞争激烈,并持续展现出强劲的增长势头。

$NZE:RUA
Treasury

市场动态:英伟达关联数据中心通过发行垃圾债券筹集46亿美元

据彭博社周二援引知情人士报道,与英伟达(NVDA)相关的内华达州数据中心项目通过发行垃圾债券筹集了45.9亿美元,凸显了人工智能基础设施融资交易的增加。 报道称,这笔交易由Tract Capital Management和Fleet Data Centers支持,五年期债券的收益率为6.74%。 该项目位于内华达州,装机容量为200兆瓦,预计将租赁给英伟达。 彭博社指出,此次交易定价正值数据中心相关股票和债券市场整体波动之际,因为人们越来越担心人工智能相关支出的快速增长能否带来预期回报。 英伟达尚未回复的置评请求。 (市场动态新闻来源于与全球市场专业人士的对话。这些信息据信来自可靠来源,但可能包含传闻和推测。准确性无法保证。)

$NVDA
Research

研究快讯:Equity Residential 2026年第一季度FFO略微超出预期,但营收不及预期

独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下:EQR公布2026年第一季度FFO为0.99美元,超出市场预期0.02美元,但7.8亿美元的租赁收入略低于预期。公司综合租赁率1.5%与去年同期持平,新租约率下降2.8%,部分原因是激励措施,但强劲的续租率(4.7%)抵消了这一降幅。我们维持“持有”评级,原因是运营费用压力将抑制2026年现金净营业收入(NOI)的增长。管理层预计2026年同店收入增长1.2%-3.2%,费用增长3.0%-4.0%,现金NOI增长0.5%-2.5%,预计2026年下半年将表现强劲。EQR的沿海市场战略持续展现价值,其中旧金山以6.5%的收入增长领跑,纽约以4.6%的增长紧随其后,而丹佛(-5.9%)和亚特兰大(-2.0%)等扩张市场则面临新的供应压力。EQR拥有高端沿海市场,这些市场新增供应有限,赋予其定价权,但较高的运营成本仍然是一个风险。EQR的在建项目总额为8.63亿美元,建成后将拥有1824套公寓。计划于2026年收购价值1.65亿美元的物业。

$EQR